Eyebright Medical announced on July 31 that it plans to use 245 million yuan of self-raised funds to acquire 51% equity of Fujian Unicon through subscribing for additional registered capital and equity transfer. Among this, the company plans to subscribe for additional registered capital of the target company with 175 million yuan, obtaining 36.84% equity after full dilution following this increase in capital (hereinafter referred to as "this capital increase"); and to transfer equity from existing shareholder Hong Kong Unicon for 70.0816 million yuan, obtaining 14.15% equity after full dilution following this equity transfer. After the completion of this transaction, the company will hold 51% of the equity of the target company (corresponding to a paid-in capital contribution ratio of 51%) and include it as a controlling subsidiary in the consolidated financial statements.
As of the date of this announcement, the target company holds seven product registration certificates for contact lenses, including certificates for transparent contact lenses. This will help diversify the company’s existing product portfolio, complement its current production lines, and is expected to become a new revenue growth point for the company.